Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Edgewise Therapeutics (EWTX) Leases (2022 - 2026)

Edgewise Therapeutics has reported Leases over the past 5 years, most recently at $1.3 million for Q1 2026.

  • Quarterly results put Leases at $1.3 million for Q1 2026, down 12.7% from a year ago — trailing twelve months through Mar 2026 was $1.3 million (down 12.7% YoY), and the annual figure for FY2025 was $1.4 million, down 11.6%.
  • Leases reached $1.3 million in Q1 2026 per EWTX's latest filing, down from $1.4 million in the prior quarter.
  • Across five years, Leases topped out at $2.4 million in Q1 2023 and bottomed at $1.3 million in Q4 2022.
  • Median Leases over the past 5 years was $1.6 million (2022), compared with a mean of $1.8 million.
  • The largest annual shift saw Leases soared 73.75% in 2023 before it crashed 30.39% in 2025.
  • Over 5 years, Leases stood at $1.3 million in 2022, then soared by 70.49% to $2.2 million in 2023, then tumbled by 30.17% to $1.6 million in 2024, then fell by 11.6% to $1.4 million in 2025, then dropped by 3.82% to $1.3 million in 2026.
  • Business Quant data shows Leases for EWTX at $1.3 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.